Prime Minister Narendra Modi (Narendra Modi) will visit the Serum Institute of India (SII) based in Pune on 28 November. A senior official gave this information on Thursday. Let us know that SII has partnered with global pharma company AstraZeneca and Oxford University for the vaccine of COVID-19. In India, the AstraZeneca vaccine will be sold under the name Kovishield.
The Central Drug Standards Control Organization has allowed seven companies to manufacture the COVID-19 vaccine for pre-clinical testing, testing and analysis. Two of these companies are Serum Institute of India and Gennova Biopharmaceuticals. Mandalayat of Pune Saurabh Rao said, “We have received confirmed information about Prime Minister Modi’s visit to Serum Institute of India on Saturday, but a detailed description of his program (minute by minute program) is not yet available.”
Representatives of more than 100 countries will also visit soon
Rao said on Tuesday that the Prime Minister is likely to come to Pune and if this happens, the objective would be to review the manufacturing status, production and distribution mechanisms of the vaccine for corona virus infection. Rao had also informed that on December 4, ambassadors and envoys of more than 100 countries will visit SII and Genova Biopharmaceuticals.
Trials have revealed good results
Recently, AstraZeneca said that its candidate vaccine AZD1222 was 70 percent effective in epidemic prevention. Interim analysis of clinical trials of vaccines in the UK and Brazil has yielded positive high level results. In trials, the vaccine is given in different patterns. Under a pattern, the effectiveness of the vaccine was 90 per cent when the first dose of AZD1222 and the second dose were given for at least one month. At the same time, 62 percent effective of the vaccine was revealed when two full doses were given for at least one month. The company says that combined trials of clinical trials show that the effectiveness of the AZD1222 vaccine candidate is 70 percent.